Concord Biotech Limited vs Lupin Limited
Last updated: 24 October 2026
Concord Biotech vs. Lupin: A MoneyDock Comparison
Concord Biotech Limited (CONCORDBIO.NS) and Lupin Limited (LUPIN.NS) are prominent players in the Indian pharmaceutical sector, making them interesting subjects for comparison. Concord Biotech specializes in fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients) and formulations, focusing on niche segments like immunosuppressants and oncology. Lupin, on the other hand, is a much larger and diversified global pharmaceutical company with a significant presence across various therapeutic areas, including cardiovascular, anti-diabetic, anti-asthma, and anti-infective segments. While both operate in the broad pharmaceutical industry, their scale, focus, and market positioning offer distinct investment profiles, making a direct comparison of their recent market performance and stability metrics valuable for investors.
Key Financial Metrics
| Metric | Concord Biotech (CONCORDBIO.NS) | Lupin (LUPIN.NS) |
|---|---|---|
| Current Price | ₹1229.30 | ₹1928.90 |
| 52-Week High | ₹1579.40 | ₹2514.80 |
| 52-Week Low | ₹1014.80 | ₹1922.00 |
| 1-Year Return | -7.65% | -8.72% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When evaluating these two companies, it's important to note the limited data available, particularly the absence of Trailing P/E and Market Cap for both, which restricts a full valuation comparison. However, we can still glean insights from the provided price and return data.
Valuation (based on current price vs. 52W High/Low): Lupin (₹1928.90) trades significantly above its 52-week low of ₹1922.00, suggesting it is currently near its yearly bottom and potentially offers a limited downside based on its recent historical range. Concord Biotech (₹1229.30), while also above its 52-week low of ₹1014.80, has a larger buffer from its lowest point compared to Lupin. Both are trading below their 52-week highs, indicating they are not at their peak valuations within the past year. Without P/E ratios, a definitive statement on whether either is 'cheap' or 'expensive' is not possible, but Lupin is currently very close to its 52-week low.
Returns: Both companies have delivered negative 1-year returns, indicating a challenging period for both stocks. Concord Biotech has a 1-year return of -7.65%, while Lupin shows a slightly worse return of -8.72%. In this aspect, Concord Biotech has marginally outperformed Lupin over the past year, experiencing a slightly less severe decline.
Stability: The 52-week range can offer some insight into volatility. Concord Biotech's range from ₹1014.80 to ₹1579.40 represents a spread of approximately 55% relative to its low. Lupin's range from ₹1922.00 to ₹2514.80 represents a narrower spread of about 30% relative to its low. A narrower range might suggest relatively less volatility or price fluctuation over the year. Additionally, Lupin's current price being very close to its 52-week low could signal either a strong support level being tested or potential for further decline if that support breaks. Without market cap data, it's difficult to assess the overall stability in terms of market influence or company size. However, based purely on price range, Lupin appears to have experienced less percentage-wise fluctuation from its low, potentially hinting at slightly more stability within its trading range over the past year, although its current position near the low could also be a concern.
MoneyDock Verdict
Aggressive Investors: Given that both stocks have seen negative returns and are below their 52-week highs, aggressive investors might look for signs of a turnaround. Lupin, being very close to its 52-week low, might present a contrarian play if fundamental outlooks improve, assuming this level holds as strong support. However, without more comprehensive financial data, it's a higher-risk bet.
Conservative Investors: The lack of P/E ratios and market capitalization for both companies makes a conservative investment recommendation challenging based solely on the provided data. Both have shown negative returns. Conservative investors might prefer to wait for more complete financial disclosures and clearer signs of stability and growth before considering either, as both are currently experiencing a downtrend.
Long-Term SIP Investors: For long-term SIP investors, the negative 1-year returns could mean opportunities for rupee-cost averaging, especially if they believe in the long-term prospects of the pharmaceutical sector and either company's specific business model. Concord Biotech has shown a slightly better (less negative) return over the past year, which might appeal to those looking for relative resilience. Lupin's position near its 52-week low could offer a lower entry point for long-term averaging if its fundamentals are strong for future growth. Thorough due diligence beyond these metrics is essential for long-term commitment to either stock.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.